There's a version of the first medical device company story we all carry around: a brilliant inventor with no industry experience who makes every classic mistake, learns expensive lessons, and either survives or does not. It's a useful story, but I don't consider it to be the most interesting one.
The interesting one is what happens when someone who has seen everything starts their first company anyway. John Schindler spent more than 25 years inside corporate medtech, from sales to management to business development at Atrium Medical, where he helped carry the iCAST covered stent, a genuinely household-name product in that world, through iteration and growth, plus senior roles beyond that. He's a MedTech Innovator alum. His company, Liquet Medical, the name is Latin for "to clear," already holds two Food and Drug Administration (FDA) clearances for its vascular drug delivery technology targeting pulmonary embolism. This is a founder who assembled regulatory and quality professionals early because, in his words, his team was smart enough to know they needed strong people in those areas from the start.
So when I had John on the podcast for an episode I'd been calling MedTech Founder 101 and asked him for the most painful reality check of the journey, I half expected a design story or a regulatory story. What I got was this: it's so much easier to innovate under the umbrella of a large corporation, where you never worry about where the check is coming from. Hang your own shingle, and suddenly building every one of those resources is your job, for a cash-hungry organization, in a capital-intensive industry. And then the confession, from a guy with three decades of commercial medtech behind him: "I'm not a natural fundraiser, and learning that process has been eye-opening."
That admission was impressive to me, because, for a first-time founder, capital is the operating system underneath regulatory, clinical, and commercial. Nearly every "founder mistake" we talked about, the medtech startup mistakes that actually sink companies, turns out to be a capital decision wearing a different costume. Let me walk through what John is doing at Liquet, because it shows what it looks like when someone plays the game with that understanding.
Every strategy is a capital strategy
Regulatory strategy is capital preservation. John is a big believer in communicating with the FDA early and often, and his reasoning is not compliance-speak. It is that you can avoid resetting timelines and spending a lot of capital unnecessarily by involving the agency before you have bet the budget on assumptions. He has watched the opposite play out, in corporate environments where teams chose to ignore advice or engaged the FDA too late. And even when the agency gives you scripted advice in a pre-submission meeting, that's a gift: now you know what you have to fund, before you have raised against the wrong plan. He pointed to a piece by regulatory professional Hal Stowe on the strategic value of a purposeful regulatory strategy, and called it something every founder should read, digest, and embrace. I'd add the flip side I hear from investors: a startup with no visible regulatory strategy is a startup that doesn't know what its next dollar is for. That's the chicken-and-egg trap: you can't afford senior regulatory help before funding, but the absence of a regulatory story costs you the funding. John's answer to that trap was negotiation, which brings me to the next point.
Everything is negotiable, especially when you're broke. One of John's core lessons: as you build your own company, everything is negotiable, so don't be afraid to negotiate. His concrete example was regulatory services. As a cash-strapped early startup, sometimes it behooves you to approach these providers with humility: we do not have a lot of cash, but what can we do to get this process started, because we want the company built on a strong foundation. There are many ways to deliver the end result. Inside a corporation you never learn this, because procurement exists and the check always clears. As a founder, stretching capital through creative structure is a survival skill.
Clinical data is enterprise value, not a checkbox. This was one of my favorite stretches of the conversation. John draws a line between clinical data and well-thought, intentional clinical data. As a startup, he says, you're trying to create strategic enterprise value, and the best way to do it is making sure your clinical evidence aligns with what is impactful economically, for payers, for reimbursement, even for clinician quality of life. Liquet is deliberate about FDA-facing endpoints, but also about secondary soft endpoints that connect the clinical dots to the cost-economic dots a hospital value analysis committee actually weighs. His phrase for it was building a ring fence around the true value of the organization. Notice what that is: a fundraising strategy executed through a clinical trial design. The study you run determines the story you can tell investors and acquirers. Design it naively and you have spent your most expensive dollars producing data that proves the wrong thing.
The valley of death is a capital-timing problem
Here is where John's situation gets uniquely instructive. Liquet has two FDA clearances, including firsts: the first FDA clearance for delivering medication into the pulmonary system this way, and for direct cardiac measurement in that environment. And investors ask him, reasonably, why are you not mass-producing these and selling them everywhere?
His answer is a masterclass in understanding what a clearance actually is. Liquet's 510(k) clearance is, as he puts it, essentially a tool claim. To market the device for the treatment of pulmonary embolism, the claim that unlocks the real market, they still need to run an investigational device exemption (IDE) trial like everyone else. Get too aggressive on sales too early and you burn capital building traction you cannot sustain, with a sales footprint you can't afford, on a claim you don't have yet, while every email a rep sends is a promotional-compliance risk. What he said made sense: some companies struggle after FDA clearance on a 510(k), before they get through that next phase, and it comes down to whether you secured the capital to make the next step.
So Liquet is doing something that looks slow and is actually fast: a limited market release timed to dovetail with the IDE trial's completion. Put the device in a small group of hands you can wrap your arms around. Learn where your nose gets bloodied. Confirm it does what you say it does. Extract a repeatable sales methodology from those early interactions. Then, when the treatment claim lands, the gloves come off and you scale into a machine you have already de-risked. Meanwhile he is raising specifically to get through contract manufacturing transfer so production can scale on the same clock.
Compare that to the tempting shortcut: sign a distribution deal with a large strategic and let their reps carry you. John has seen that movie play out before. The startup loses control of the environment, cannot drive the sales force or set its objectives, gets locked into inventory commitments, and if the reps are not compensated to pull your product out of the bag, it falls to the bottom of the bag and stays there, even when the product is wonderful. Distribution is not evil; some products suit it. But taken as a substitute for capital, it usually costs more than it saves.
This is also where 510(k) clearance delays belong in the conversation. Every month lost to a preventable deficiency letter is a schedule slip and runway burning at a fixed rate against a milestone your next raise is priced on. The teams that treat submission readiness casually are making a financing decision without realizing it.
The foundation you should be building
If capital is the operating system, the quality foundation is what determines how efficiently it runs. And I did not have to make this argument myself, because John made it for me, unprompted. Liquet is a Greenlight Guru customer, and near the end of our conversation he offered this to the audience: there is real utility in having your eQMS set up as early in the process as you can, because it streamlines things and makes everything so much easier when it comes time for the submission.
That's the cost-of-doing-nothing math from a founder living it. The DIY route, quality system scattered across spreadsheets and shared drives, feels free right up until the submission crunch, when reconstructing your design history becomes its own unfunded project on the critical path. And notice it is the same logic as everything else John does: build the thing before the moment you need it, because building it under pressure costs multiples. The nuance, and it matters, is that early does not mean heavyweight. A ten-person company running a big-company quality apparatus burns capital the other way. The goal is a system sized to your stage that grows with you, which is exactly the right-sizing idea we keep coming back to on this blog.
One more from John's toolkit that costs almost nothing and saves fortunes: "The Mom Test," Rob Fitzpatrick's book on customer discovery. Never ask your mom if your idea is good, because she will always say yes, and clinicians being polite to an eager founder will do the same. Be purposeful about how you open questions with clinicians to arrive at the real problem. For Liquet the real problem was concrete: physicians treating pulmonary embolism have no good way to know when to stop delivering clot-busting medication, short of hauling the patient to serial CTs, so clots get left behind and turn into scar tissue. A catheter that reads pulmonary pressure in real time through the bedside monitor they already know how to use answers a question doctors actually have. That is falling in love with the patient's problem instead of your technology, and it is also, once again, capital efficiency: discovery done right means every downstream dollar is spent on a device the market has already told you it wants.
What this means if it's your first company
We've covered founder fundamentals on this show before, and if you want the broad map, the startup survival guide conversation with Steve Bell is a great place to start. This piece is intentionally narrower. It is about the one gap that experience does not close, because John's story proves the point: 25 years of commercial medtech, a veteran team, strong advisors, and the thing that still demanded new muscle was raising and deploying capital.
So if you are building your first medical device company, borrow his lens. Before your next strategic decision, regulatory pathway, trial design, launch model, quality system, ask the question John's journey keeps answering: what does this choice do to the capital I have, the capital I need, and the story I will tell to get it? Talk to the FDA before you spend against assumptions. Design endpoints that build enterprise value, not just clearance. Time your launch to your evidence and your bank account, not your excitement. Negotiate everything. And set the foundation, quality system included, while it is cheap, because every one of these gets brutally expensive the moment you need it and do not have it.
The technology gets you in the game. The capital discipline keeps you in it.
Keep reading
If you are thinking through your own capital and quality strategy as a first-time founder, these related guides go deeper on the specific pieces:
- 5 mistakes to avoid when seeking funding for your medical device
- 7 common mistakes that can delay your FDA 510(k) clearance
- Right-sizing your QMS
- 7 tips to attract investors and raise funds for your medical device
- How to communicate your regulatory strategy to medical device investors
- MedTech startup survival guide with Steve Bell
If you are building the quality foundation this early, Ultralight by Greenlight Guru gives lean, product-led teams just enough QMS to stay audit-ready without slowing down. Get a demo of Ultralight today →
BONUS RESOURCE: Checklist: What medical device investors want to see
